BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Wednesday, March 19, 2025
Breaking News: BioWorld by Clarivate releases comprehensive 2024 year in review
See today's BioWorld Science
Home
» Betta Pharmaceuticals describes new ER-α degradation inducers for cancer
To read the full story,
subscribe
or
sign in
.
Cancer
Betta Pharmaceuticals describes new ER-α degradation inducers for cancer
Feb. 15, 2024
Betta Pharmaceuticals Co. Ltd. has identified estrogen receptor α (ER-α; ESR1) degradation inducers reported to be useful for the treatment of cancer.
BioWorld Science
Cancer
Patents
